Treatment of Venous Thromboembolism and Long-Term Prevention of Recurrence: Present Treatment Options and Ximelagatran

被引:0
|
作者
Henry Eriksson
机构
[1] Sahlgrenska University Hospital/Östra,Department of Medicine
来源
Drugs | 2004年 / 64卷
关键词
Warfarin; Deep Vein Thrombosis; International Normalise Ratio; Enoxaparin; Venous Thromboembolism;
D O I
暂无
中图分类号
学科分类号
摘要
Despite the effectiveness of anticoagulant therapy for the treatment of acute venous thromboembolism and the prevention of recurrent venous thromboembolism, existing antithrombotic therapies are suboptimal. Unfractionated heparin, low-molecular-weight heparin (LMWH) and warfarin have practical limitations and carry the risk of treatment-related adverse events that restrict their clinical benefits and reduce cost-effectiveness. Efforts to achieve optimal venous thromboembolism prophylaxis by modifying the intensity of oral warfarin treatment have produced equivocal results, and there is a need for new, efficacious antithrombotic drugs providing predictable, well-tolerated oral dosing without the need for coagulation monitoring. Such agents would ideally have no significant food or drug interactions, and be suitable for both short- and long-term treatment. Ximelagatran, the first oral direct thrombin inhibitor, has the potential to fulfill many of the unmet needs in the management of venous thromboembolism.
引用
收藏
页码:37 / 46
页数:9
相关论文
共 50 条
  • [1] Treatment of venous thromboembolism and long-term prevention of recurrence: Present treatment options and ximelagatran
    Eriksson, H
    [J]. DRUGS, 2004, 64 (Suppl 1) : 37 - 46
  • [2] Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran
    Eriksson, H
    Lundström, T
    Wåhlander, K
    Clason, SB
    Schulman, S
    [J]. THROMBOSIS AND HAEMOSTASIS, 2005, 94 (03) : 522 - 527
  • [3] Long-term treatment of venous thromboembolism
    Kearon, Clive
    Kahn, Susan R.
    [J]. BLOOD, 2020, 135 (05) : 317 - 325
  • [4] Long-term treatment for venous thromboembolism
    Couturaud, F
    Kearon, C
    [J]. CURRENT OPINION IN HEMATOLOGY, 2000, 7 (05) : 302 - 308
  • [5] Long-term Treatment of Venous Thromboembolism
    Becattini, Cecilia
    Manina, Giorgia
    [J]. CURRENT VASCULAR PHARMACOLOGY, 2014, 12 (03) : 384 - 392
  • [6] Treatment and Long-Term Management of Venous Thromboembolism
    Al-Badri, Ahmed
    Spyropoulos, Alex C.
    [J]. CLINICS IN LABORATORY MEDICINE, 2014, 34 (03) : 519 - 536
  • [7] The role of ximelagatran in the treatment of venous thromboembolism
    Schulman, S
    [J]. PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2005, 34 : 18 - 24
  • [8] Economic Analysis of Rivaroxaban for the Treatment and Long-Term Prevention of Venous Thromboembolism in Portugal
    Santos, Isabel Fonseca
    Pereira, Sonia
    Mcleod, Euan
    Guillermin, Anne-Laure
    Chatzitheofilou, Ismini
    [J]. ACTA MEDICA PORTUGUESA, 2014, 27 (05): : 615 - 624
  • [9] Fondaparinux in the initial and long-term treatment of venous thromboembolism
    Pesavento, Raffaele
    Amitrano, Maria
    Trujillo-Santos, Javier
    Di Micco, Pierpaolo
    Mangiacapra, Sara
    Lopez-Jimenez, Luciano
    Falga, Conxita
    Garcia-Bragado, Fernando
    Piovella, Chiara
    Prandoni, Paolo
    Monreal, Manuel
    [J]. THROMBOSIS RESEARCH, 2015, 135 (02) : 311 - 317
  • [10] Ximelagatran for secondary prevention of venous thromboembolism
    Böger, C
    Schroll, S
    Holmer, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (06): : 618 - 618